Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ablexis' Pharmaceutical Consortium

This article was originally published in Start Up

Executive Summary

Ablexis LLC's October 2010 consortium-based alliance with Pfizer Inc. and four other undisclosed "Top 15" drugmakers represents an important new variation in platform-technology deal-making.
Advertisement

Related Content

Forma To Play To Its Strengths WIth Genentech Deal
Oncology Start-up Cyterix Pharmaceuticals Launches With $9.2MM From VCs
Investing A La Carte: Making Separate Bets on Discovery and Development to Boost Near-Term Returns
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2010
Start-Up Quarterly Statistics, Q4 2010
The A-List: 2010's Trend-Shaping Series A Financings
Valuing Early-Stage Pharma Deals
Pharma: Serious About Change?
In the Midst Of A Shakeout, Biotech VCs Must Embrace New Partners, New Math
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091906

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel